TETRACYCLINE HYDROCHLORIDE | N050263 | LEDERLE LABORATORIES DIV AMERICAN CYANAMID CO
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 4 | Not Yet Recruiting | Qilu Hospital of Shandong University | 492 | 2026-09-01 → 2027-12-30 | |
| Phase 2 | Completed | Instituto Nacional de Cancerologia de Mexico | 107 | 2010-12 → 2014-11 | |
| N/A | Completed | Alliance for Clinical Trials in Oncology | 130 | 2004-12 → 2009-07 | |
| Phase 4 | Completed | Johns Hopkins University | 1,452 | 2001-08 → 2006-12 | |
| Phase 3 | Completed | University of California, San Francisco | 47,605 | 2015-12-05 → 2024-12-31 | |
| N/A | Completed | Yale University | 27 | 2015-03-12 → 2017-04-19 | |
| Phase 1 | Completed | Yale University | 10 | 2013-07-08 → 2015-11-05 | |
| N/A | Completed | University of South Florida | 25 | 2012-04 → 2015-09 | |
| Phase 2 | Completed | Huntington Medical Research Institutes | 13 | 2011-09 → 2012-10 | |
| N/A | UNKNOWN | Guangzhou University of Traditional Chinese Medicine | 110 | 2019-06-12 → 2022-12 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
5 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
No patent or exclusivity listings for this strength.